Bispecific antibody for hemophilia treatment and deliveries to treatment centers and patient homes

Delivery of a bispecific antibody mimicking active factor VIII, including administration kits, for the treatment of hemophilia A with inhibitor as part of the 'National Program for the Treatment of Hemophilia and Related Bleeding Disorders 2024-2028': Deliveries will take place in 2026-2027 to hemophilia treatment centers and patient homes for 85 patients; the guaranteed minimum quantity totals 462,000 mg, with 154,000 mg in 2026 and 308,000 mg in 2027. The scope also includes organizing deliveries, collecting and disposing of single-use equipment and medical waste, implementing an electronic diary for consumption control, preparing information materials, training all patients in safe product use, and providing medical waste containers that meet legal requirements.

Tender documents

Additional details